U.S. markets closed

CRISPR Therapeutics AG (CRSP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
101.46-6.24 (-5.79%)
At close: 4:00PM EDT

101.40 -0.06 (-0.06%)
After hours: 4:26PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close107.70
Open107.01
Bid101.33 x 1000
Ask101.39 x 1000
Day's Range100.63 - 107.10
52 Week Range54.00 - 220.20
Volume1,673,093
Avg. Volume1,934,806
Market Cap7.688B
Beta (5Y Monthly)2.24
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer
    Benzinga

    Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer

    Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all the R&D costs and any worldwide profits, 50/50. CRISPR and Nkarta will start with a CAR-NK candidate targeting CD70 primarily for oncology indications. The target for their second CAR-NK program has yet to be revealed. In addition to those programs, Nkarta can license CRISPR’s technology to edit five gene targets in an unlimited number of its own NK cell therapies. For each non-collaboration candidate including a gene-editing target licensed from CRISPR, Nkarta will owe the company milestones and royalties on net sales. The agreement includes a three-year exclusivity period between the companies. Price Action: NKTX shares gained 8.96% at $20.18, while CRSP shares are up 2.62% at $110.67 on the last check Friday. See more from BenzingaClick here for options trades from BenzingaCronos Q1 Earnings Impacted By COVID-19 Related RestrictionsAnalysts React To FDA AdCom Vote On ChemoCentryx's Avacopan, Stock Plunges© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • With 1 Cure Behind It, This Breakthrough Biotech Takes Aim at a Bigger Market
    Motley Fool

    With 1 Cure Behind It, This Breakthrough Biotech Takes Aim at a Bigger Market

    Long before they won the 2020 Nobel Prize in Chemistry for discovering the molecular gene-editing tool known as clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, Jennifer Doudna and Emmanuelle Charpentier dreamed of Victoria Gray, a woman with sickle cell disease. Although they didn't know her, they knew that one day, a patient with a genetic disease would be cured using their discovery. Sickle cell disease was the logical place to start since it's the most common blood disorder with a single-gene mutation.

  • This Bold Statement by the Vertex CEO Means a New Blockbuster May be Here Soon
    Motley Fool

    This Bold Statement by the Vertex CEO Means a New Blockbuster May be Here Soon

    Vertex Pharmaceuticals (NASDAQ: VRTX) is the leader in cystic fibrosis (CF) treatment -- and it expects to hold that title until at least the late 2030s. The biotech company may be about to prove that, yes, it can. Vertex CEO Reshma Kewalramani made a statement about one of the company's most innovative, exciting programs during the recent earnings call.